PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
43.00%
Revenue growth under 50% of CSIQ's 184.23%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
23.23%
Gross profit growth under 50% of CSIQ's 184.23%. Michael Burry would be concerned about a severe competitive disadvantage.
49.67%
EBIT growth below 50% of CSIQ's 252.97%. Michael Burry would suspect deeper competitive or cost structure issues.
49.67%
Operating income growth under 50% of CSIQ's 252.97%. Michael Burry would be concerned about deeper cost or sales issues.
139.84%
Positive net income growth while CSIQ is negative. John Neff might see a big relative performance advantage.
110.69%
Positive EPS growth while CSIQ is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
109.67%
Positive diluted EPS growth while CSIQ is negative. John Neff might view this as a strong relative advantage in controlling dilution.
162.28%
Share change of 162.28% while CSIQ is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
187.19%
Diluted share change of 187.19% while CSIQ is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-7700.00%
Negative OCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.87%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-78.34%
Negative 10Y revenue/share CAGR while CSIQ stands at 437.77%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-78.34%
Negative 5Y CAGR while CSIQ stands at 437.77%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-78.34%
Negative 3Y CAGR while CSIQ stands at 437.77%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
97.87%
OCF/share CAGR of 97.87% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
97.87%
OCF/share CAGR of 97.87% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
97.87%
3Y OCF/share CAGR of 97.87% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
100.20%
Positive 10Y CAGR while CSIQ is negative. John Neff might see a substantial advantage in bottom-line trajectory.
100.20%
Positive 5Y CAGR while CSIQ is negative. John Neff might view this as a strong mid-term relative advantage.
100.20%
Positive short-term CAGR while CSIQ is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.40%
AR growth of 25.40% while CSIQ is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
31.67%
Inventory growth of 31.67% while CSIQ is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
4.21%
Asset growth of 4.21% while CSIQ is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-61.69%
We have a declining book value while CSIQ shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
234.90%
R&D growth of 234.90% while CSIQ is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
329.37%
SG&A growth of 329.37% while CSIQ is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.